Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Neogenomics Inc (NEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 672,335
  • Shares Outstanding, K 78,820
  • Annual Sales, $ 244,080 K
  • Annual Income, $ -5,720 K
  • 36-Month Beta 0.98
  • Price/Sales 2.78
  • Price/Cash Flow 18.98
  • Price/Book 4.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.49 +13.22%
on 04/06/17
8.67 -2.19%
on 04/20/17
+0.83 (+10.85%)
since 03/24/17
3-Month
7.49 +13.22%
on 04/06/17
8.67 -2.19%
on 04/20/17
+0.10 (+1.19%)
since 01/24/17
52-Week
6.90 +22.90%
on 10/26/16
9.88 -14.17%
on 12/13/16
+1.32 (+18.44%)
since 04/22/16

Most Recent Stories

More News
NeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017

FT. MYERS, FL--(Marketwired - April 14, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2017 financial results on Wednesday, April 26, 2017.

NEO : 8.45 (-0.94%)
NeoGenomics Schedules its Q1 2017 Earnings Release for April 26, 2017

FT. MYERS, FL--(Marketwired - April 14, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its first quarter 2017 financial results on Wednesday, April 26, 2017.

NEO : 8.45 (-0.94%)
Moving Average Crossover Alert: NeoGenomics (NEO)

NeoGenomics, Inc. (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

NEO : 8.45 (-0.94%)
NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

Migration of all Clarient Clients to NeoGenomics Lab Information System Now Complete

NEO : 8.45 (-0.94%)
NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016

Migration of all Clarient Clients to NeoGenomics Lab Information System Now Complete

NEO : 8.45 (-0.94%)
NeoGenomics Schedules its Q4 and Full Year 2016 Earnings Release for February 22, 2017

FT. MYERS, FL--(Marketwired - February 08, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter and full year 2016 financial results on Wednesday, February...

NEO : 8.45 (-0.94%)
NeoGenomics Schedules its Q4 and Full Year 2016 Earnings Release for February 22, 2017

FT. MYERS, FL--(Marketwired - February 08, 2017) - NeoGenomics, Inc. (NASDAQ: NEO) announced today that it plans to release its fourth quarter and full year 2016 financial results on Wednesday, February...

NEO : 8.45 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Support & Resistance

2nd Resistance Point 8.74
1st Resistance Point 8.64
Last Price 8.45
1st Support Level 8.44
2nd Support Level 8.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.